Janux Therapeutics Inc (JANX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $695.65M
Last updated: Nov 17, 2026 at 4:18 PM ET
Janux Therapeutics Inc (JANX) Statistics
Janux Therapeutics (JANX) has a market cap of $695.65M and an enterprise value of $653.84M. Revenue grew 1994.69% over the last 12 months from the 12 months before. It kept -320.35% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 6.01% below the market cap, as cash exceeds debt.
| Market Cap | $695.65M |
|---|---|
| Enterprise Value | $653.84M |
| Latest price (Nov 17, 2026) | $10.71 |
Key Dates
The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 29.0x and 0.7x. Its year-end P/S ranged from 47.9x to 157.9x from 2021 to 2025.
| P/S Ratio | 29.0x |
|---|---|
| Forward P/S | 25.4x |
| P/B Ratio | 0.7x |
Price Statistics
The stock is down 63.42% over 52 weeks and trades 34.81% below its 50-day average.
| Beta (1Y) | 0.92 |
|---|---|
| 52-Week Change | -63.42% |
| 1-Month Change | -36.02% |
| 3-Month Change | -38.87% |
| 6-Month Change | -22.45% |
| 5-Year Change | -28.25% |
| Total Return (1Y) | -63.42% |
| Total Return (3Y CAGR) | +7.25% |
| Total Return (5Y CAGR) | -10.85% |
| Return vs SPY (1Y) | -74.65% |
| Max Drawdown (1Y) | -69.17% |
| Max Drawdown (3Y) | -83.98% |
| Sharpe Ratio (1Y) | -1.05 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $16.43 |
| 200-Day Average | $15.33 |
| 52-Week Range | $10.73 to $35.34 |
| RSI (14 Days) | 27.1 |
| Average Volume (20 Days) | 1.03M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 17.69x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 17.69x |
|---|---|
| Quick Ratio | 17.69x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -10.95% over the last 12 months, against a 5-year average of -12.83%.
| Return on Equity (ROE) | -10.95% |
|---|---|
| Return on Assets (ROA) | -10.15% |
| ROE (5Y Average) | -12.83% |
| ROA (5Y Average) | -11.82% |
| ROIC (5Y Average) | -13.02% |
| Asset Turnover | 0.03x |
| Receivables Turnover | 83.17x |
Scores
JANX has an Altman Z-Score of 5.69, in the safe zone above 2.99, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 5.69 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $31.17M over the last 12 months.
| Revenue | $31.17M |
|---|---|
| Revenue Growth (YoY) | +1994.69% |
| Gross Profit | $22.23M |
| Operating Income | -$139.56M |
| Pretax Income | -$99.85M |
| Net Income | -$99.85M |
| Reported EPS (TTM) | -$1.59 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 92.68% of the $983.65M in total assets.
| Cash and Equivalents | $41.82M |
|---|---|
| Total Debt | $0 |
| Net Cash | $41.82M |
| Net Cash Per Share | $0.66 |
| Working Capital | $905.13M |
| Shareholder Equity | $911.61M |
| Book Value Per Share | $14.45 |
| Total Assets | $983.65M |
| Total Liabilities | $72.04M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $583.00K of capital spending, operating cash flow left -$54.16M of free cash flow.
| Operating Cash Flow | -$53.58M |
|---|---|
| Capital Expenditures | $583.00K |
| Free Cash Flow | -$54.16M |
| FCF Per Share | -$0.89 |
| Depreciation and Amortization | $14.22M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -447.76%.
| Gross Margin | 71.32% |
|---|---|
| Operating Margin | -447.76% |
| Pretax Margin | -320.35% |
| Net Margin | -320.35% |
| FCF Margin | -173.76% |
Growth
Revenue grew 5.11% a year over 3 years.
| Revenue Growth (3Y CAGR) | +5.11% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | +44.68% |
| Tangible Book Per Share Growth (2Y CAGR) | +44.68% |
Dividends and Yields
JANX does not pay a dividend. Its free cash flow yield is -8.02%.
| FCF Yield | -8.02% |
|---|---|
| Buyback Yield | 0.00% |
| Shareholder Yield | 0.00% |
Peer Position
Against 8 similar companies, JANX has the 3rd highest P/S.
P/S RatioPeer median 8.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -36.25%
| P/S Ratio | 29.0x vs 8.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +1994.69% vs -36.25% median |
Analyst Forecast
Consensus estimates put revenue growth at -12.41% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -12.41% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About JANX
What is JANX's market cap?
Janux Therapeutics has a market cap of $695.65M. Its enterprise value, which adds debt and subtracts cash, is $653.84M.
How many shares of JANX are outstanding?
Janux Therapeutics has 63.09M shares outstanding. The count is up 1.72% from a year earlier.
Does JANX pay a dividend?
No. Janux Therapeutics does not pay a dividend.
How much debt does JANX have?
Janux Therapeutics has $0 of total debt and $41.82M of cash and equivalents, a net cash position of $41.82M.
JANX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors